Retatrutide Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Retatrutide dosing: protocols and safety.
Dose Range
1,000–12,000 mcg (1–12 mg) per week
Frequency
Once weekly subcutaneous injection
Cycle Length
Ongoing; dose escalation over 24+ weeks
Half-Life
~6 days (plasma, albumin-bound)
Administration Routes
Quick Reconstitution Calculator
Calculate syringe units instantly
Syringe Draw
10.0 units
2500 mcg/ml · 0.100 ml draw
For laboratory research use only. This tool performs reconstitution math (concentration and syringe-unit conversion) and is not dosing guidance for humans or animals.
Dosing Protocols
This stage builds tolerance with a slow uptitration that follows the Phase 2 trial schedule.
Retatrutide Phase 2 uptitration protocol: weeks 1-20
| Week | Dose | Notes |
|---|---|---|
| 1-4 | 2 mg weekly SC | Starting dose; expect mild nausea, dose-related GI effects |
| 5-8 | 4 mg weekly SC | First titration step; most users tolerate well |
| 9-12 | 4 or 8 mg weekly SC | Optional hold at 4 mg if GI tolerance is borderline |
| 13-16 | 8 mg weekly SC | Second titration step; weight loss accelerating |
| 17-20 | 8 or 12 mg weekly SC | Optional hold at 8 mg; many users see substantial weight loss at 8 mg and don't escalate |
- Inject subcutaneously in the abdomen (2+ inches from the navel) and rotate sites weekly.
- Inject on the same day each week. Time of day is not critical; many users prefer evenings to sleep through the initial nausea.
- Use a 29-31G × 1/2" insulin syringe or the supplied pen device.
What to expect at each dose
- At 2 mg, expect 4-6 weeks of mild nausea as the GI tract adapts, and modest weight loss (~2-3 kg by week 4).
- At 4 mg, appetite suppression becomes noticeable and weight loss accelerates (~4-6 kg by week 8).
- At 8 mg, appetite suppression and satiety are significant, weight loss is substantial (~10-15 kg by week 16) and nausea often resolves.
- 12 mg, the maximum dose, brings continued weight loss and a higher side-effect burden; per Phase 2 data, most weight-loss gains occur at this dose.
Required monitoring for beginners
- At baseline, check fasting glucose, HbA1c, lipid panel, CMP, liver function, thyroid, weight, BMI, blood pressure and resting heart rate (seated, post-rest).
- At week 4, check blood pressure, heart rate and fasting glucose, and assess subjective tolerance.
- At week 12, run the full panel plus weight and body composition.
- At week 20, run the full panel at the target dose.
When not to proceed to the next titration step
- If nausea or vomiting limits food intake or causes dehydration, hold the current dose.
- If heart rate rises >20 bpm from baseline, hold and get a cardiology consult.
- With any chest pain, severe abdominal pain or signs of pancreatitis, stop immediately.
Caveats for 2026 biohacker use
Retatrutide is not FDA-approved. It is usually sourced from research-chemical vendors (with substantial quality variation) or compounding pharmacies (where available). Purity and identity verification by HPLC and mass spec is essential, more so than for established FDA-approved drugs. See the Best Peptide Vendors 2026 guide.
The aim here is to hold the weight loss at the target dose and optimize body composition and metabolic effect.
Retatrutide maintenance: weeks 20-52 (after successful uptitration)
- The target dose is 8-12 mg weekly SC, individualized by tolerance and weight-loss trajectory.
- Most users settle at 8 mg weekly, which captures ~75-80% of the weight loss with ~60-70% of the side effects.
- 12 mg weekly gives maximum efficacy but the highest side-effect burden, so it is reserved for users with stronger weight-loss goals or T2DM or NAFLD indications.
Stack considerations at maintenance
- Metformin 500-1000 mg/day is a standard adjunct in T2DM.
- Ipamorelin plus CJC-1295 or tesamorelin is the canonical body recomposition stack for lean mass preservation during the retatrutide-induced caloric deficit. Time the GHS injection opposite the retatrutide peak (its 6-day half-life makes scheduling flexible).
- MK-677 is an oral GHS alternative for lean mass preservation. MK-677 stimulates appetite while retatrutide suppresses it, and the opposing signals net out to a moderated appetite.
- Creatine 5 g/day is standard for lean mass preservation.
- Protein at 0.8-1.0 g/lb bodyweight is essential during any GLP-1-class-induced caloric deficit to preserve lean mass.
Weight loss plateau management
Expect weight loss to slow after 36-48 weeks. To keep progressing:
- Strength training 3-5x weekly is the most effective plateau-breaker, and the lean mass it adds increases BMR.
- Raise protein to 1.0-1.2 g/lb bodyweight in late-stage weight loss.
- Reassess the dose: at 8 mg, consider escalating to 12 mg to break the plateau.
- Adding or escalating a GHS stack amplifies lean mass preservation.
- Resist escalating by reflex. Not all plateaus require a higher dose, and some are a natural adjustment to a new steady state.
Cycling vs continuous therapy
Retatrutide is designed as a chronic therapy, like semaglutide in obesity. Cycling is not clinically indicated and typically brings rapid weight regain (6-10% in 6 months after discontinuation, consistent with GLP-1 class data). If cycling anyway for non-medical reasons:
- Consider tapering to 2 mg over 4-8 weeks rather than stopping abruptly.
- Without continued behavior change or bridge therapy, weight regain is almost universal.
- A bridge to lower-potency semaglutide may reduce regain but is uncommon in practice.
Bloodwork on maintenance
- Every 12 weeks, check fasting glucose, HbA1c, lipid panel, liver function, thyroid, blood pressure, weight and resting heart rate.
- Every 6 months, run the full panel plus DEXA or another body composition measurement.
- Annually, run the full panel with a cardiovascular assessment and reassess the continued indication.
This protocol adapts retatrutide to specific indications beyond general weight loss (NAFLD/MASH, T2DM, cardiovascular risk reduction) for experienced users with full lab monitoring.
NAFLD / MASH protocol: 48 weeks
The Sanyal 2024 data showed an 85% relative reduction in hepatic fat at 12 mg weekly for 48 weeks. With imaging-confirmed NAFLD (hepatic fat fraction >5%):
- Dose at 8-12 mg weekly (titrate to the maximum tolerated).
- Continue for 48 weeks at minimum, longer for persistent MASH.
- Monitor ALT/AST monthly and MRI-PDFF or FibroScan quarterly.
- As adjuncts, tesamorelin 2 mg/day SC adds to hepatic fat reduction through GH-driven lipid mobilization, and NAD+ or NMN supports mitochondrial function under the heavier fat-oxidation load.
T2DM optimization
- 8 mg weekly is typically enough for an HbA1c reduction equivalent to tirzepatide's.
- Metformin 1000 mg/day is the standard co-therapy; withdraw sulfonylureas or reduce their dose to prevent hypoglycemia.
- Check HbA1c every 8 weeks during titration and every 12 weeks on maintenance, and fasting glucose weekly during uptitration.
- An SGLT2 inhibitor (empagliflozin 10-25 mg/day) is synergistic for cardiorenal benefit and can be added after the retatrutide dose stabilizes.
Cardiovascular risk reduction
Phase 2 data showed BP falling ~11/5 mmHg and triglycerides ~30%, a meaningful change in cardiovascular risk beyond weight loss alone. With known CVD or high CVD risk:
- Use the standard 8-12 mg weekly dose.
- Consider adding a statin if not already on one; retatrutide plus a statin reduces LDL-C synergistically.
- Treat any blood pressure elevation with an ACE inhibitor or ARB.
- Assess cardiovascular status regularly, possibly with ambulatory BP monitoring and an echocardiogram at 6-12 months.
Body recomposition for experienced athletes
Retatrutide with a full GHS stack is the most potent recomposition configuration available:
- Retatrutide 8-12 mg weekly (the caloric-deficit engine)
- Tesamorelin 2 mg/day plus ipamorelin 200 mcg in the same pre-bed injection, for lean mass preservation and VAT reduction
- Protein 1.0-1.2 g/lb bodyweight
- Resistance training 4-5x weekly
- Creatine 5 g/day
Expected outcome: 20-25% body weight loss over 48 weeks, with 85-90% of the loss from fat mass and VAT reduced preferentially.
Contraindications specific to advanced dosing
- Active malignancy (absolute)
- Personal or family history of MTC or MEN-2 (absolute)
- Active pancreatitis or a history of pancreatitis (absolute)
- Active gallbladder disease (relative)
- Resting tachycardia (resting HR >90), whose cause should be investigated first
- Severe heart failure (NYHA III-IV), a relative contraindication with limited data
Weight-Based Dosing
Commonly Stacked With
Tier 1: GHS peptides for lean mass preservation (recommended)
- Tesamorelin plus ipamorelin is the canonical body-recomposition stack. GLP-1-class weight loss produces 15-20% lean mass loss alongside fat loss; tesamorelin plus ipamorelin preserves lean mass and preferentially targets visceral fat. Both go in one injection, pre-bed. For retatrutide users who put body composition ahead of scale weight, this combination is the most evidence-based stack.
- CJC-1295 plus ipamorelin is the alternative GHRH + ghrelin stack: research-grade rather than FDA-approved like tesamorelin, and cheaper.
- MK-677 is an oral GHS alternative with an opposing appetite signal (MK-677 stimulates, retatrutide suppresses); many users find 10 mg of MK-677 ideal for balancing the two mechanisms.
Tier 2: metabolic co-therapies
- Metformin 500-1000 mg/day is standard background therapy in T2DM.
- BPC-157 plus TB-500 is for connective tissue repair, useful during weight loss when training stresses the joints or GI dysmotility causes discomfort.
- NAD+ or NMN gives mitochondrial support during the metabolic shift to fat oxidation and is particularly useful in NAFLD protocols.
- A statin, if there is CVD risk, is synergistic with retatrutide for LDL-C reduction.
- An SGLT2 inhibitor (empagliflozin, dapagliflozin) offers cardiorenal synergy in T2DM and can be added after the retatrutide dose stabilizes.
Tier 3: longevity-focused stacks
- Epithalon suits a longevity stack; retatrutide's metabolic benefits align with longevity-oriented interventions.
- MOTS-c, a mitochondrial peptide, has theoretical synergy with retatrutide's metabolic effects.
Do not stack
- Other GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, dulaglutide) are redundant at GLP-1R and add GI side-effect burden without additional benefit. Switch between these drugs rather than stacking them.
- Sulfonylureas at standard doses risk hypoglycemia in T2DM patients; reduce or discontinue them during retatrutide titration.
- Do not stack other triple or dual agonists in development: they are experimental compounds at the same receptors.
Transition protocols
Switching from semaglutide to retatrutide:
- Discontinue semaglutide, wait 7 days (one half-life) and start retatrutide at 2 mg.
- Then follow the standard uptitration.
- Some users find this easier to tolerate than starting de novo, because they have already acclimated to the GI effects.
Switching from tirzepatide to retatrutide:
- The approach is similar: discontinue tirzepatide, wait 7 days and start retatrutide at 2 mg.
- Users often find they can escalate faster (weeks 5-8 at 4 mg rather than a full titration restart) thanks to GLP-1/GIP acclimation.
- Monitor closely for glucagon-specific side effects (fasting glucose and heart rate).
Side Effects & Safety
Contraindications
**Absolute contraindications** - A personal or family history of medullary thyroid carcinoma (MTC) rules it out, given the GLP-1 class rodent carcinogenicity signal. - So does Multiple Endocrine Neoplasia syndrome type 2 (MEN-2), on the same signal. - With a history of acute pancreatitis, retatrutide carries a recurrence risk (a GLP-1 class signal). - The GLP-1 class worsens active gallbladder disease or acute cholecystitis. - Active malignancy is relative to absolute depending on type; the GLP-1 class has some residual oncology concerns. - With no safety data, avoid it in pregnancy or when planning pregnancy. - Breastfeeding has no safety data either. - No pediatric data exist for retatrutide (age <18). Some GLP-1 class drugs have pediatric obesity approvals; retatrutide does not. - The GLP-1 mechanism would dramatically worsen severe gastroparesis or gastric outlet obstruction. **Relative contraindications (consult physician before use)** - A history of chronic pancreatitis raises recurrence risk. - Rapid glycemic correction can worsen active proliferative diabetic retinopathy. - Investigate the cause of resting tachycardia (HR >90 at baseline) first, since retatrutide consistently raises HR. - Data in severe heart failure (NYHA III-IV) are limited, and the heart rate elevation may be problematic. - Appetite suppression is dangerous with an active eating disorder (anorexia nervosa or bulimia). - Severe hepatic impairment (Child-Pugh C) matters because hepatic clearance is primary. - Data in severe chronic kidney disease (eGFR <30) are limited. **Drug interactions** - Sulfonylureas (glipizide, glyburide) raise hypoglycemia risk; reduce their dose 50% when starting retatrutide. - Insulin also raises hypoglycemia risk; reduce the insulin dose at retatrutide initiation. - Other GLP-1 receptor agonists are redundant; discontinue them before starting retatrutide. - With warfarin, the GLP-1 class may alter INR; monitor more frequently at dose changes. - GLP-1-induced gastric delay may reduce oral contraceptive efficacy; consider non-oral contraception during active uptitration. - Gastric delay may reduce acetaminophen (paracetamol) Cmax, usually not to a clinically significant degree. - At dose changes, monitor any drug with a narrow therapeutic index that requires predictable absorption. **Specific populations requiring extra caution** - People with a history of depression or suicidal ideation need monitoring, since some GLP-1 class drugs have FDA adverse event signals for suicidality. - A history of retinopathy calls for annual ophthalmology during rapid weight loss. - After bariatric surgery, GLP-1 class data are limited and absorption may be altered. **Monitoring requirements** - At baseline, check fasting glucose, HbA1c, lipid panel, CMP, liver function, thyroid (TSH + free T4), blood pressure and resting heart rate (seated, post-rest), plus a pregnancy test in women of childbearing age and an eye exam if diabetic or high-risk. - Every 4 weeks during uptitration, check fasting glucose, blood pressure, heart rate, weight and subjective tolerance. - Every 12 weeks on maintenance, check HbA1c, liver function, lipids, weight and body composition. - Annually, repeat the full panel plus a cardiovascular assessment, and ophthalmology if diabetic. **Discontinuation criteria** Stop retatrutide and consult a clinician on any of these: - Severe persistent GI symptoms limiting food intake - Any suspected pancreatitis symptoms (severe abdominal pain radiating to back) - Severe hypoglycemia (glucose <54 mg/dL) - Resting HR >100 bpm or new arrhythmia - Severe depression or suicidal ideation - Acute gallbladder symptoms - Unexplained dehydration or electrolyte derangement - Planning pregnancy
Additional Notes
The target therapeutic range is 8-12 mg once weekly SC at maintenance, after successful uptitration.
Standard uptitration schedule (from Phase 2 Jastreboff 2023)
- Weeks 1-4: 2 mg weekly
- Weeks 5-8: 4 mg weekly
- Weeks 9-12: 4 or 8 mg (individualized)
- Weeks 13-16: 8 mg weekly
- Weeks 17-20: 8 or 12 mg weekly (individualized)
Dose adjustments based on tolerance
- For mild to moderate nausea, continue the current dose 1-2 additional weeks before escalating; it usually resolves.
- For severe nausea or vomiting, or for dehydration, reduce to the previous dose and re-attempt escalation after 4+ weeks of tolerance.
- If heart rate rises >20 bpm above baseline, hold the dose, get a cardiology consult and consider a dose reduction.
Timing
- Inject once weekly, on the same day each week.
- Time of day is not critical (the 6-day half-life produces stable plasma levels), but many users prefer evening injections to sleep through the initial nausea.
- For a missed dose, take it as soon as remembered if <3 days late; if >3 days late, skip it and resume at the usual time (do not double-dose).
- Inject subcutaneously in the abdomen (at least 2 inches from the navel) and rotate sites weekly; the thigh or upper arm are alternatives.
Dose conversions (based on standard reconstitution)
Retatrutide is typically supplied as a 5 mg/mL or 10 mg/mL solution for SC injection (research-use vials). For the 5 mg/mL concentration:
| Target Dose | Volume | Insulin Syringe Units |
|---|---|---|
| 2 mg | 0.4 mL | 40 units |
| 4 mg | 0.8 mL | 80 units |
| 8 mg | 1.6 mL | requires 3 mL syringe |
| 12 mg | 2.4 mL | requires 3 mL syringe |
For 10 mg/mL (more concentrated):
| Target Dose | Volume | Insulin Syringe Units |
|---|---|---|
| 2 mg | 0.2 mL | 20 units |
| 4 mg | 0.4 mL | 40 units |
| 8 mg | 0.8 mL | 80 units |
| 12 mg | 1.2 mL | requires 3 mL syringe |
Interactions with nutrition
- Food does not meaningfully affect SC retatrutide absorption (unlike oral drugs).
- Alcohol has no direct interaction but can exacerbate nausea in the days after injection.
- Caffeine is neutral.
- High-fat meals may trigger nausea or GI upset in users sensitive to the gastric delay.
Dose adjustments in specific populations
- Retatrutide is predominantly hepatically cleared, so mild to moderate renal impairment does not require adjustment; data in severe CKD are limited.
- In hepatic impairment, use with caution and monitor liver function more frequently.
- Above age 75, where data are limited, uptitrate more slowly: start at 2 mg and hold 8 weeks before escalation.
- In active T2DM, reduce or discontinue sulfonylureas and insulin during uptitration to prevent hypoglycemia.
See the Retatrutide Dosage Guide for protocol specifics.
Frequently Asked Questions
What is the recommended Retatrutide dosage?
The typical dose range for Retatrutide is 1,000–12,000 mcg (1–12 mg) per week. It is usually administered Once weekly subcutaneous injection. Always start with the lowest effective dose.
How often should I take Retatrutide?
Once weekly subcutaneous injection
Does Retatrutide need to be cycled?
Yes, typical cycle length is Ongoing; dose escalation over 24+ weeks.
What are Retatrutide side effects?
Retatrutide has a GLP-1-class side-effect profile, with additional considerations from its GIP and glucagon receptor components. **Common (>10% of Phase 2 participants)** - Nausea, the most frequent adverse event, is dose-related, typically worst in the first 2-4 weeks of each titration step, and resolves with continued dosing. Most cases are mild to moderate; severe nausea affects ~10-15% at the 12 mg dose. - Vomiting, also dose-related, is more frequent than on semaglutide or tirzepatide at equivalent weight-loss rates. - Diarrhea is common across the GLP-1 class. - Constipation is less common than nausea but still frequent. - Decreased appetite is the therapeutic effect; it can be uncomfortable at first and causes some patients to discontinue. - Injection site reactions (mild erythema, pruritus) are usually transient. - Dyspepsia and eructation reflect GLP-1-mediated gastric delay. **Uncommon (1-10%)** - Heart rate rises a mean ~6-8 bpm, more than on semaglutide or tirzepatide (likely glucagon receptor-mediated). It is usually asymptomatic, but monitor patients with baseline cardiac concerns. - ALT and AST rise modestly, a mild hepatic enzyme elevation of unclear mechanism; monitor them. - Fatigue or lethargy, likely multifactorial, is more common than with semaglutide. - Hypoglycemia is rare as monotherapy but can occur with sulfonylureas or insulin, which then need a dose adjustment. - Gallbladder events (cholelithiasis, cholecystitis) are a GLP-1 class effect, with no retatrutide-specific signal beyond the class. **Rare but important** - Acute pancreatitis is a rare GLP-1 class signal (~<0.5%). Stop immediately and investigate if it is suspected. - Severe gastrointestinal events (gastroparesis, ileus or gastric retention) are rare but consistent with the GLP-1 class mechanism. - Thyroid C-cell tumors and MTC are a GLP-1 class signal from rodent carcinogenicity studies; MEN-2 and a personal or family history of MTC are absolute contraindications. - Diabetic retinopathy has progressed with rapid glycemic correction in GLP-1 trials, so monitor diabetic patients. **Retatrutide-specific considerations (triple-agonist trade-offs)** - The GI burden is higher at the maximal dose: 12 mg is associated with substantially more nausea and vomiting than semaglutide 2.4 mg or tirzepatide 15 mg. Users should uptitrate slowly and may need to hold at an intermediate dose (4-8 mg) if 12 mg is not tolerated. - Heart rate elevation, consistent with glucagon receptor pharmacology, is the most clinically distinctive side effect versus other GLP-1-class drugs. Anyone with a baseline resting HR >90 or any cardiac history should discuss it with a cardiologist. - Dysesthesia (unpleasant abnormal skin sensations) was reported in the Phase 3 trials. On 12 mg it occurred in 12.5% of participants in TRIUMPH-1 against 0.9% on placebo (Lilly's topline), 7% in TRIUMPH-2 against 1% (the published Lancet paper) and 20.9% in TRIUMPH-4 against 0.7% (Lilly's topline), and was generally mild to moderate. - Long-term effects are unknown. Peer-reviewed data run to 80 weeks (TRIUMPH-1 and TRIUMPH-2, published 29 September 2026), Lilly's toplines add 104 weeks in one extension, and longer-term safety is extrapolated from GLP-1 class plus glucagon pharmacology. **What users should monitor** - At baseline, check fasting glucose, HbA1c, lipid panel, comprehensive metabolic panel, liver function, thyroid, blood pressure and resting heart rate, plus a pregnancy test in women of childbearing age. - Every 4 weeks during uptitration, check fasting glucose, blood pressure, heart rate and subjective GI tolerance. - Every 12 weeks on maintenance, check HbA1c, weight, liver function and lipids. - Annually, repeat the full panel plus a cardiovascular assessment.
Where can I buy Retatrutide?
Compare 11 listings from 5 vendors on our price comparison page, starting from $79.99.
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.